Introduction: Next-generation sequencing (NGS) of cellfree circulating tumor DNA (cfDNA) enables noninvasive genomic analysis of NSCLC patients. Although plasmadetected genomic alterations (GAs) have been shown to predict targeted therapy response, evidence of durability of response is lacking or limited to small cohorts as is the impact of cfDNA NGS results on clinical decisions.
Introduction
Targeting key oncogenic alterations is a critical determinant in the care of lung cancer patients. Targeted therapies matched with driver oncogenes significantly prolong the overall survival of advanced lung cancer patients in academic-as well as community-based practice settings. [1] [2] [3] [4] Molecular testing for somatic genomic mutations in EGFR and BRAF, and rearrangements of the ALK receptor tyrosine kinase (ALK) and ROS1 genes are associated with targeted therapy response rates two-to three-fold higher than with cytotoxic chemotherapy. [5] [6] [7] [8] [9] Other lung cancer targetable genomic driver aberrations include ERBB2 (HER2), RET, MET, and NTRK.
2,10-14 Today, standard-of-care molecular tests include using multiplex polymerase chain reaction (PCR), mass spectrometry, immunohistochemistry (IHC), and fluorescent in situ hybridization, but these may have limited sensitivity and/or be restricted to common hotspot mutations and oncogenes. [15] [16] [17] Next-generation sequencing (NGS), also known as massively parallel sequencing, represents an effective way to capture more comprehensive genomic information. 18 Hybrid capture-based NGS assays not only allow the identification of hotspot mutations but also interrogate the entire coding sequence of oncogenes and tumor suppressor genes and the introns of selected genes involved in gene fusions and allow assessment of copy number alterations. 2 By testing beyond the most common hotspot oncogenic aberrations in NSCLC, NGS has identified targetable genomic abnormalities not tested for or missed with less sensitive methods such as quantitative PCR, IHC, or fluorescent in situ hybridization. 16, 19, 20 Genotyping tumor tissue in search of actionable genetic alterations has become routine practice in clinical oncology. 18 Yet, it has been estimated that approximately 25% to 50% of lung carcinoma patients have no or insufficient tissue available for genotyping. [20] [21] [22] In addition, tumor tissue reflects a single snapshot in time, and 6-month old archival tissue may not reveal targetable mutations acquired under treatment pressure. 23, 24 Finally, tissue biopsy procedures are an uncomfortable, invasive, and expose the patient to clinical complications. [25] [26] [27] Recent advances have enabled increasingly complex genomic data to be derived from a patient's peripheral blood, commonly known as liquid biopsy. 28 Fragmented circulating tumor DNA is found in the cellfree component of whole blood. It is released into the bloodstream by apoptosis or necrosis, or active secretion by tumor cells, and the load of circulating tumor DNA correlates with tumor staging and prognosis. [28] [29] [30] The ability to isolate circulating tumor DNA from cell-free (cfDNA) in peripheral blood allows noninvasive molecular profiling of the tumor. NGS of cfDNA from peripheral blood via hybrid capture enables comprehensive genomic analysis. 31 It may identify targetable mutations at diagnosis when tissue genotyping is infeasible or incomplete, as well as at progression when treatment fails, rather than relying on a static time point. 29, 32 Furthermore, liquid biopsies may be useful in monitoring tumor burden and could potentially detect minimal residual disease after surgery or therapy with curative intent. 29, 33 Liquid biopsy specimens may capture a more global picture of tumor heterogeneity than tissue biopsy specimens. 31, 34 Comprehensive cfDNA NGS testing has been shown to have excellent specificity, and high but imperfect sensitivity due to low tumor shedding. 35, 36 Through the use of molecular barcoding and stringent bioinformatic algorithms, targeted cfDNA NGS panels can now make accurate calls in 95% of samples down to 0.2% to 0.25% allele fractions. 35, 36 Comprehensive genomic testing is defined as reporting all four major types of somatic alterations: point mutations, indels, fusions, and copy number amplifications (CNAs), and complete sequencing of critical exons, meaning those exons which harbor sensitizing or resistance alterations such as exons 18-21 in the EGFR gene.
Although there are numerous outcomes studies using cfDNA NGS in NSCLC, duration of response is lacking or limited to small cohorts and there is insufficient data in regard to the impact of cfDNA analysis on clinical decision making. 13, 14, 17, 22, 23, 30, 34, [37] [38] [39] The goals of this study were to evaluate the clinical utility of comprehensive cfDNA testing with a well validated 54 to 68 gene targeted sequencing assay on clinical decision making, treatment response, and progression-free survival (PFS).
Materials and Methods

Patients
This retrospective cohort study included 116 sequential patients with advanced NSCLC who underwent clinical cfDNA NGS testing (Guardant360; Guardant Health, Inc., Redwood, California) between 2014 and 2017 in Israel.
The patients in the study have clinically, pathologically, and radiologically confirmed NSCLC, and were initially diagnosed with advanced disease or progressed to metastatic disease as part of the natural course of their disease. cfDNA analysis was performed upon recommendation of the treating physician in patients with advanced disease. Both smokers and never-smokers, and patients of various ages were included. Patients were tested upfront due to lack of tissue or after negative or limited (generally EGFR and ALK only) local standard-ofcare molecular tissue analysis, or at progression after one or more treatment lines. Clinical characteristics of the patients were extracted from the patients' medical and electronic health records.
Blood Samples and cfDNA Isolation
Blood was collected in Streck tubes (Streck, La Vista, Nebraska) during routine phlebotomy, and samples were shipped at room temperature overnight to California from Israel. Blood (10 mL) was processed upon receipt to isolate plasma by double centrifugation at 4 C. Plasma was immediately aliquoted and stored at À70 C. cfDNA was extracted from 1-mL aliquots of plasma using the QIAamp circulating nucleic acid kit (Qiagen, Hilden, Germany), concentrated using Agencourt Ampure XP beads (Beckman Coulter, Brea, California), and quantified by Qubit fluorometer (Life Technologies, Carlsbad, California). All cfDNA sequencing and analysis was performed at Guardant Health, Inc., (Redwood City, Calif), a Clinical Laboratory Improvement Amendmentscertified, College of American Pathologists-accredited, New York State Department of Health-approved clinical laboratory.
cfDNA Sequencing
Barcoded sequencing libraries were generated from 5 to 30 ng of cfDNA. Two different clinical testing panels were used during the study period. For samples received in the laboratory before February 4, 2015 (n ¼ 10), a 54-gene panel was used. For samples received in the laboratory on or after February 4, 2015 (n ¼ 106), a 68-gene panel was used. Exons were captured using biotinylated custom bait oligonucleotides (Agilent, Santa Clara, California), resulting in a 78,000 base-pair (78 kb) and 138,000 base-pair capture footprint on the 54-gene panel and 68-gene panel, respectively. Samples were paired-end sequenced on an Illumina Hi-Seq 2500 (San Diego, California), followed by algorithmic reconstruction of the digitized sequencing signals. The analytic and clinical validation of this assay is described elsewhere. 33, 35, 36 The coverage depth across all coding sequence in all samples averaged approximately 10,000x. Illumina sequencing reads were mapped to the hg19/GRCh37 human reference sequence, and genomic alterations in cfDNA were identified from Illumina sequencing data by Guardant Health's proprietary bioinformatics algorithms. These algorithms quantify the absolute number of unique DNA fragments at a given nucleotide position, thereby enabling circulating tumor DNA to be measured as a quantitative percentage of total cfDNA. The mutant allele percentage for a given mutation was calculated as the fraction of cfDNA molecules harboring that mutation divided by the total number of unique cfDNA molecules mapping to the position of the mutation. For gene CNAs, plasma copy number of 2.5 to 4.0 is reported as þþ amplification and copy number greater than 4.0 as þþþ amplification, representing the 50th to 90th and greater than 90th percentiles, respectively, of all CNA calls in the Guardant360 database.
Data Analysis
This study was focused on genomic alterations (GAs) with potential clinical relevance. Clinical actionability of cfDNA results was assessed for each patient and included driver genomic alterations with US Food and Drug Administration (FDA) approved targeted therapy in NSCLC and/or FDA-approved targeted therapy available in a different cancer type (OncoKB levels of evidence 1, 2A, 2B, and R1). 40 A subsequent analysis included GAs with appropriate, evidence-based targeted agents, as recommended by the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC (levels of evidence 1 and 2A). GAs associated with investigational treatments were not included in the current analysis, although four patients went on to participate in a driver-based clinical trial.
The analysis was performed for the entire cohort and for sub-groups of patients, divided according to the time when cfDNA analysis was performed ( Fig. 1) : patients with cfDNA analysis before first-line therapy (group A); patients with cfDNA analysis on progression on chemotherapy or immunotherapy (group B1); and patients with cfDNA analysis after progression on EGFR tyrosine kinase inhibitors (TKIs) (group B2).
Best response to targeted therapy after plasma-based comprehensive genomic testing was measured using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. 41 Response was not evaluable at the time of analysis for two patients because of early cessation of the targeted therapy due to toxicity.
Results
Patient Characteristics
Demographic and clinical characteristics of 116 patients are shown in Table 1 . Age at diagnosis ranged between 30 and 97 years, with a median age of 63 years. Sex ratio was 1:1.7 (M:F). Of 116 patients, 40% (n ¼ 47) were never-smokers. Eighty-three percent (n ¼ 96) of patients had a diagnosis of lung adenocarcinoma; 89% (n ¼ 104) were diagnosed at stage III or IV. The remaining 11% (n ¼ 12) who were either stage I or II at the time of diagnosis, had cfDNA analysis on progression to stage III-IV disease.
Thirty-seven percent (n ¼ 43) had one metastatic site while performing cfDNA analysis, 33% (n ¼ 38) had two metastatic sites, and 16% (n ¼ 19) had three or more metastatic sites. Twelve percent (n ¼ 14) had no active metastatic sites, either at stage IIIB disease or previously metastatic patients after successful radiation therapy.
Out 116 patients, 41% (n ¼ 48 of 116) had cfDNA analysis before first-line therapy (group A), 35% (n ¼ 40 of 116) on progression on chemotherapy or immunotherapy (group B1), and 24% (n ¼ 28 of 116) after progression on EGFR TKIs (group B2).
Among the untreated patients (group A), 52% (n ¼ 25 of 48) were post negative tissue analysis and 37.5% (n ¼ 18 of 48) were as salvage testing due to lack of tissue specimen. The rest decided to perform upfront testing in parallel to tissue analysis.
Among group B1, 77.5% (n ¼ 31 of 40) were post negative tissue analysis for EGFR and 20% (n ¼ 8 of 40) lacked tissue specimens. One patient was ALK-positive on IHC and had cfDNA analysis after progression on three lines of targeted treatment. Nine other patients had nonstandard molecular tests; only one of them was positive for an MET actionable genomic alteration, received targeted treatment, and performed cfDNA analysis after progression.
Actionable GAs
One or more actionable GAs with associated FDAapproved (on/off-label) treatment was detected in 65% of our cohort (75 of 116 patients). Among them, 65% (n ¼ 31 of 48) were treatment-naive patients (group A), 52.5% (n ¼ 21 of 40) were patients who progressed on chemotherapy or immunotherapy (group B1), and 82% (n ¼ 23 of 28) were patients who progressed on EGFR TKI (group B2). Across 116 patient samples tested, a total of 154 individual actionable GAs were found, with a median of 1 alteration (range, 0-9) per sample. Out 116 patients, in 35% (n ¼ 41) no actionable alterations were detected, in 32% (n ¼ 37) 1 actionable alteration was detected, in 22% (n ¼ 25) 2 actionable mutations were detected, and in 11% (n ¼ 13) 3 or more actionable alterations were detected. These alterations are summarized in Supplemental Figure 1 .
The most common oncogenic driver alterations among the total study group were EGFR sensitizing mutations (25.9%, 30 of 116), KRAS (16.1%, 14 of 116), other EGFR aberrations such as EGFR amplifications (9.5%, 11 of 116), MET exon 14 skipping or amplifications (8.6%, 10 of 116), and PIK3CA mutations (8.6%, 10 of 116). Among untreated patients (group A), the most common drivers were EGFR sensitizing mutations (20.8%, 10 of 48), KRAS (12.5%, 6 of 48), and BRAF non-V600E (8.3%, 4 of 48). Among patients who progressed on chemotherapy or immunotherapy (group B), the most common drivers were KRAS (17.5%, 7 of 40), ERBB2 (HER2) mutations and indels (10%, 4 of 40), and MET alterations (10%, 4 of 40). Among patients who progressed on EGFR TKIs (group C), the most common alterations were EGFR sensitizing mutations (64.3%, 18 of 28), EGFR T790M mutations (28.6%, n ¼ 8 of 28), and EGFR amplifications (21.4%, 6 of 28).
Clinically Relevant GAs
GAs with an available targeted therapy based on the NCCN guidelines NSCLC were identified in 41% (n ¼ 48 of 116) of patients, with 74 individual actionable GAs found and summarized in Figure 2 . 10 In 15% (n ¼ 17 of 116), more than one actionable alteration was identified. The targetable sensitizing or resistance mutations identified were EGFR-sensitizing mutations (25.9%, n ¼ 30 of 116), MET amplifications and/or exon 14 skipping mutations or resistance point mutation (9.5%, n ¼ 11 of 116), EGFR T790M mutations (6.9%, n ¼ 8 of 116), ERBB2 (HER2) mutations (5.2%, n ¼ 6 of 116), RET rearrangements (4.3%, n ¼ 5 of 116), BRAF V600E mutations (1.7%, n ¼ 2 of 116), and ALK rearrangements or resistance point mutation (1.7%, n ¼ 2 of 116). Lung cancer-related actionable GAs were identified in 31% (n ¼ 15 of 48) of group A, 32.5% (n ¼ 13 of 40) of group B1, and 71% (n ¼ 20 of 28) of group B2 patients. Clinically relevant actionable GAs were found in 23% (10 of 43) of patients with one metastatic site, 39.5% (15 of 38) of patients with two metastatic sites, and 53% (10 of 19) of patients with three or more metastatic sites. In patients without active metastatic sites no clinically relevant GAs were found. By cfDNA, we were able to follow seven patients who progressed on osimertinib (among group B2). In six of seven patients, EGFR T790M became undetectable on subsequent cfDNA analyses, with one showing increased EGFR T790M on subsequent cfDNA analysis 6.5 months later. Four new actionable GAs had emerged on progression: EGFR G719A (one of seven patients), EML4-ALK fusion (one of seven patients), ERBB2 R143Q (one of seven patients), and EGFR C797S (one of seven patients). Misdiagnosed or previously false-negative targetable driver GAs by local hospital-based laboratory testing were detected in 6% (3 of 48), 2.5% (1 of 40), and 0% (0 of 28) patients for groups A, B1, and B2, respectively. Focusing on liquid biopsy at progression, five patients with EGFR T790M missed on tissue testing were identified with the current plasma-based testing (group B2, 18%), raising the prevalence of EGFR T790M mutations among group B2 patients to 46% (13 of 28 patients).
Changes in Treatment Decisions
Of the 48 patients with NCCN-based labels, 30 were treated accordingly (Supplemental Fig. 2, Table 2 ), with an overall decision impact rate of 26% (n ¼ 30 of 116). The impact rate was 23% (n ¼ 11 of 48) in group A, 25% (n ¼ 10 of 40) in group B1 and 32% (n ¼ 9 of 28) in group B2 patients.
In addition to the 30 patients who received targeted therapy, four other patients were detected with an actionable mutation according to NCCN guidelines, but did not receive targeted treatment due to deterioration or death before initiation of treatment; one other patient was detected with an active known sensitizing EGFR mutation, after prior progression on EGFR TKI, which allowed the continuation of targeted treatment; and one patient was detected with a targetable MET mutation, but because of positive programmed death ligand 1 received immunotherapy.
Outcomes of Targeted Therapy
Best response to targeted therapy after plasma-based comprehensive genomic testing, as measured using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST), is summarized in Figure 3 . 41 Of 30 patients treated with targeted therapy, 93% (n ¼ 28) were evaluable for tumor response. For patients who were treated by targeted therapy, the overall response rate (ORR) was 43% (12 of 28 patients) and the disease control rate was 75% (21 of 28 patients). The total ORR was 44% (four of nine patients) and the durable disease control rate (DCR) was 100% (nine of nine patients) for group A; the ORR was 30% (n ¼ 3 of 10) and the DCR was 50% (5 of 10) for group B1; and the ORR was 55.5% (five of nine) and the DCR was 78% (seven of nine) for group B2.
Four percent (n ¼ 1 of 28) of patients experienced complete response (CR) to targeted therapy (EGFR T790M with osimertinib) and remain progression-free at 13 months.
Thirty-nine percent (n ¼ 11 of 28) of patients showed a partial response (PR) with an average of 62.5% tumor shrinkage. Six patients with EGFR sensitizing mutations (exon 19 deletions and L858R) received first-/second-generation EGFR TKIs (n ¼ 3) or third-generation EGFR TKI (n ¼ 3 Group B2: Upon progression on EFGR-TKIs (n = 28) Figure 2 . Targetable genomic driver prevalence (%) according to National Comprehensive Cancer Network guidelines for NSCLC among the total study group (top), group A (upper middle), group B (lower middle), and group B2 (bottom). As some patients performed multiple cell-free DNA (cfDNA) analyses, the prevalence analysis is based on genomic drivers found in all positive cfDNA-analysis reports performed for each patient. Prior negative reports did not enter the calculation, partly because suppression of driver alterations by treatment may have falsely lowered their prevalence.
glucose positron-emission tomography/computed tomography) response and another patient with EGFR exon 19 deletion with gefitinib remain progressionfree at 29 and 18.5 months, respectively. One with EGFR L858R with gefitinib passed away from disease progression. One patient with L858R with a complete metabolic response and two patients with exon 19 deletions with osimertinib, two of them as part of a clinical trial, remain progression-free at 11, 11, and 8 months, respectively. For two patients with EGFR T790M with osimertinib (one of them as part of a clinical trial), one remains progression-free at 12 months, whereas the other passed away from disease progression. For two patients with MET exon 14 skipping mutations and/or amplification with crizotinib, one remained progression-free for 9 months and one passed away from disease progression. One patient with ALK G1202R resistance mutation with lorlatinib remained progression-free for 9 months. Thirty-two percent (n ¼ 9 of 28) of patients experienced stable disease (SD): three patients had KIF5B-RET fusion with cabozantinib; one patient with EGFR exon 19 deletion with gefitinib received treatment for 9 months until EGFR T790M was found on a molecular test (plasma-based "hotspot" NGS). For two patients with ERBB2 (HER2) mutations (n ¼ 1) and amplification (n ¼ 1) with ado-trastuzumab emtansine, the former received treatment for 17 months with slow disease progression whereas the latter showed a mixed response. One patient had EGFR T790M with osimertinib as a compassionate treatment; one BRAF V600E with a combination of vemurafenib and trametinib; and one patient with EGFR VUS with off-protocol afatinib.
Twenty-five percent (n ¼ 7 of 28) of patients experienced progressive disease. Two patients had EGFR T790M with osimertinib, one of them in combination with erlotinib as a compassionate treatment. One patient had CCDC6-RET fusion with alectinib. Two patients had ERBB2 (HER2) mutations, one with trastuzumab and one with ado-trastuzumab emtansine. One patient had multiple MNNG Hos transforming gene (MET) mutations with c-MET inhibitors as part of a phase II clinical trial. One patient had EGFR exon 19 deletion with third-line gefitinib who was not tested for EGFR or ALK at diagnosis due to insufficient tissue; a cfDNA analysis was performed after progression on previous lines of nontargeted treatment. Median PFS was 7.3 months for group A, 2.5 months for group B1, and 3.3 months for group B2. PFS is shown in Supplemental Figure 3 .
Median time-to-next-treatment (TTNT) was 9 months for group A, 3.5 months for group B1, and 4 months for group B2. TTNT is also shown in Figure 3 .
Duration of Response
The duration of response to targeted therapy is shown in Figure 4 . Duration of response ranged between 0.5 to 29 months, with a median of 5 months. Forty-three percent (n ¼ 13 of 30) of patients had a durable disease control of more than 4 months since response start until progression.
Low Mutation Allele Frequencies Response to Targeted Therapy
Variant allele frequencies (VAFs) or CNAs were available for 28 of 30 patients who received targeted therapy (Fig. 3) . In this group of patients, VAFs ranged between 0.1% and 62.8%, with a mean VAF value of 8.3%. Patients who showed a CR or PR according to RECIST criteria had VAFs that ranged between 0.2% and 62.8% with a mean VAF value of 11.6%. Patients who experienced SD had VAFs that ranged between 0.1% and 14.5% with a mean VAF value of 3.9%. Patients who experienced progressive disease (PD) had VAFs that ranged between 0.2% and 53.4% with a mean VAF value of 8.5%.
EGFR T790M to EGFR sensitizing driver ratio, a reflection of clonality versus subclonality of acquired resistance mutations, ranged between 5.3% and 82.9%, with a mean value of 47.8%. Patients who showed a CR or PR had an EGFR T790M driver ratio that ranged between 33.3% and 66.7% with a mean VAF value of 47.6%. One patient who experienced SD had an EGFR T790M driver ratio of 82.9%. Patients who experienced PD had an EGFR T790M driver ratio that ranged between of 5.3% and 55.6% with a mean VAF value of 30%, highlighting the lack of association between the degree of subclonality and response. 
Discussion
This is the largest reported study of durable outcomes using plasma-based comprehensive genomic testing. We find that response and DCRs for targeting of plasma-detected GAs are equivalent to published studies of tissue-based mutations both in the first-line and second-line, at expected two-to three-fold improvements in response rates over cytotoxic chemotherapy. [30] [31] [32] The main finding in this study is the important role of comprehensive cfDNA NGS in naïve as Table C. well as in previously treated patients. CfDNA NGS was able to salvage tissue exhaustion or reversed falsenegative tissue analysis (mostly using PCR testing). The role of cfDNA in the EGFR progressors has been also previously reported in the AURA study 6 ; however, our cfDNA NGS approach explored more targets rather than just T790M and with a higher rate of T790M detection (28.6% in group B2). This finding is expected due to the higher sensitivity of the cfDNA NGS method used in our study versus the Roche Cobas T790M plasma test used in AURA. 42 The clinical utility of cfDNA NGS is confirmed by its impact here on changes in treatment decisions. The impact rate was 23% for patients who performed naïve cfDNA analysis and 25% for patients who performed cfDNA analysis on progression on chemotherapy or immunotherapy. For patients at progression on EGFR TKIs, we changed treatment in 32%. Treatment changes were impacted when local non-NGS tests missed targetable alterations, when tissue was unobtainable or a quantity not sufficient for genotyping, or at progression when repeat invasive tissue biopsy was declined by the patient or medically contraindicated. Clinical outcomes of targeted therapy given as a result of cfDNA analysis showed an ORR of 43% and a DCR of 75%. Most of the patients who responded poorly or progressed rapidly were on higher lines of therapy, whereas most patients with earlier lines of therapy had a better and more durable response.
Although the number of patients was limited, we found no relation between VAF and targeted therapy response, validating earlier findings for EGFR T790M in the AURA study and for multiple GAs in the NEXT-2 study. 37, 43 As in NEXT-2 we saw no relationship between the ratio of the EGFR T790M allele fraction to the EGFR truncal driver mutation, suggesting that either subclonal T790M levels may respond, or possibly that plasma-detected T790M might reflect response in one lesion but that its allele fraction could be diluted by other EGFR-driven tumors not harboring T790M. The subclonality findings in our cohort and NEXT-2 were not consistent with AURA where an EGFR T790M/driver ratio less than 10% correlated with worse response. 43 In addition, we report PFS of 7.3 months for upfront, 2.5 months for post-chemo/immunotherapy, and 3.3 months for post-EGFR TKIs lines of targeted therapy comparable to tissue-based targeted therapy. PFS was shorter for the genomic targets such as RET fusions or ERBB2 mutations/amplification where more potent drugs are needed or not accessible to us in Israel either off-label or via clinical trials (such as Loxo-292 or BLU-667 for RET fusions or combination neratinib plus trastuzumab for ERBB2). Moreover, although ERBB2 mutations are thought to be more clinically relevant than gene amplifications in lung cancer, there are reports of responses to treatment of HER2 amplification detected by NGS to trastuzumab emtansine; therefore, both types of HER2 alterations were considered as potentially targetable in this study. 44 PFS was closer to expected for EGFR and ALK where we had access to potent targeted TKIs, including the fourth-generation ALK TKI lorlatinib for the ALK G1202R resistance mutation. Previous studies lacked duration of response, reported here as TTNT, or PFS, except in smaller series. The targeted therapy outcomes reported here are consistent with and build upon more than a dozen published studies (excluding single-patient case reports) using the same cfDNA NGS test, Guardant360. 4, [13] [14] 17, [22] [23] 30, 34, [37] [38] [39] [45] [46] [47] Treatment outcome studies are the gold standard for validation of genomic diagnostic tests, as concordance between plasma-and tissue-based tests is challenged by tumor spatial and temporal (acquired resistance) heterogeneity or suppression of tumor DNA shedding by treatment.
Limitations of this study include its retrospective nature, although the response and DCRs are consistent with two previous prospective studies. 23, 37 Also, more than half of the at-progression patients were in the third line of treatment or higher, where response rates would be expected to be lower than published studies of second-line targeted therapies. Response rate, survival, and duration of treatment in this study population, which is enriched for plasma-positive patients with limited or failed tumor tissue genotyping, may introduce theoretical selection bias as cfDNA may be more likely to be positive in patients with aggressively growing metastases whereas single lesion biopsy-based genotyping is indifferent to whether disease is indolent or aggressive. If true, however, then the plasma-based treatment results become more, rather than less, compelling. Nonetheless, the clinical outcomes reported in this study reflected the real-life impact. Because patients were not randomized, and cfDNA testing ordered on those with a higher pre-test probability of mutation (female, nonsmoking, etc.) the prevalence of GAs here may be higher than a cohort enrolled by randomization. 48 Undergenotyping is a serious problem, with many advanced NSCLC patients not being tested for all seven NCCN-guideline-recommended genomic targets. A recent report found that almost one-third of patients are not being tested for EGFR and ALK, 75% are not tested for ROS1, and 85% are not tested for BRAF V600E or MET amp and exon 14 skipping. 4 This impacts patient care in several ways. First, cytotoxic chemotherapy exposes patients to higher complication rates than targeted therapies, and costs of infusion and emergency room visits and hospitalizations are also higher. Specifically, cytotoxic chemotherapy is associated with a doubling of annual health care costs over erlotinib, and a four-fold increase when biologicals such as bevacizumab are included. 49 Secondly, EGFR, ALK, and ROS1 alterations are negative predictors of immunotherapy response, and when tissue genotyping is infeasible or incomplete, these genes can be assessed with cfDNA NGS. 50, 51 This study extends the evidence for clinical utility of comprehensive plasma-based cfDNA NGS testing by showing durability of response. cfDNA NGS changed treatment decisions in a significant number of patients in this retrospective study. It also reduced undergenotyping of advanced NSCLC patients, while reducing costs and complications of repeat invasive biopsies, and facilitating more precise use of targeted therapy and immunotherapy.
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